These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36107752)

  • 21. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
    Fàbrega-Ferrer M; Herrera-Morandé A; Muriel-Goñi S; Pérez-Saavedra J; Bueno P; Castro V; Garaigorta U; Gastaminza P; Coll M
    Antiviral Res; 2022 Dec; 208():105458. PubMed ID: 36336176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.
    Cooper MS; Zhang L; Ibrahim M; Zhang K; Sun X; Röske J; Göhl M; Brönstrup M; Cowell JK; Sauerhering L; Becker S; Vangeel L; Jochmans D; Neyts J; Rox K; Marsh GP; Maple HJ; Hilgenfeld R
    J Med Chem; 2022 Oct; 65(19):13328-13342. PubMed ID: 36179320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
    Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
    Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
    J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M
    Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D
    Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.
    Wang F; Zeng R; Qiao J; Xia A; Li Y; Li F; Wu Y; Liu Y; Zhao X; Lei J; Yang S
    Bioorg Med Chem Lett; 2023 Aug; 92():129407. PubMed ID: 37437852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
    Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
    Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
    [No Abstract]   [Full Text] [Related]  

  • 35. Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.
    Ren P; Yu C; Zhang R; Nie T; Hu Q; Li H; Zhang X; Zhang X; Li S; Liu L; Dai W; Li J; Xu Y; Su H; Zhang L; Liu H; Bai F
    Eur J Med Chem; 2023 Mar; 249():115129. PubMed ID: 36702052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor.
    Clyde A; Galanie S; Kneller DW; Ma H; Babuji Y; Blaiszik B; Brace A; Brettin T; Chard K; Chard R; Coates L; Foster I; Hauner D; Kertesz V; Kumar N; Lee H; Li Z; Merzky A; Schmidt JG; Tan L; Titov M; Trifan A; Turilli M; Van Dam H; Chennubhotla SC; Jha S; Kovalevsky A; Ramanathan A; Head MS; Stevens R
    J Chem Inf Model; 2022 Jan; 62(1):116-128. PubMed ID: 34793155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.